Skip to main content
Delfa

← All trials/NCT07820111

CompletedPhase 3

Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial

GLP-RA , DIABETIC , NON-DIABETIC , BMI ,TYG-index , HDL-C

Lead sponsor

Zagazig University

Assets

Dulaglutide / Semaglutide / Tirzepatide

Listed sites

1

Recruiting sites

-

Actual enrollment

159

Study population

Obesity / overweight, Type 2 diabetes

Eligibility highlights

-

Primary endpoint

•Body weight at 3 and 6 months

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07820111
Org study IDKACST,KSA:H-11-N-136

Timeline

Milestones

Study start2025-10-18actual
Primary completion2026-03-17actual
Study completion2026-03-17actual
Study first posted2026-09-15actual
Last update posted2026-09-15actual

Assets

Investigational agents

DulaglutideSemaglutideTirzepatide

Who this study enrolls

Obesity / overweightType 2 diabetes

Who can enroll

Minimum age18 Years
Maximum age65 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

•overweight or obese, diabetic, or non-diabetic

Exclusion criteria

•Patients who will refuse to be enrolled in the study or refuse to sign the consent

Endpoints (9)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiometabolic biomarkers
4
Weight & body composition
2
MASH / liver
2
Glycemic / diabetes
1

Weight & body composition

2 endpoints
Primary/protocol endpoint

change in body weight at 3 and 6 months

Time frame:6-MONTH STUDY PERIOD

change from baseline, improvement

Secondary/protocol endpoint

Change in Body Mass Index (BMI)

Time frame:3 months, and 6 months

change from baseline, improvement

Glycemic / diabetes

1 endpoint
Secondary/protocol endpoint

Change in Glycated Hemoglobin (HbA1c)

Time frame:Baseline, 3 months, and 6 months

change from baseline, improvement

MASH / liver

2 endpoints
Secondary/protocol endpoint

Change in Alanine Aminotransferase (ALT)

Time frame:Baseline, 3 months, and 6 months

change from baseline, improvement

Secondary/protocol endpoint

Change in Aspartate Aminotransferase (AST)

Time frame:Baseline, 3 months, and 6 months

change from baseline, improvement

Cardiometabolic biomarkers

4 endpoints
Secondary/protocol endpoint

Change in Low-Density Lipoprotein Cholesterol (LDL-C)

Time frame:Baseline, 3 months, and 6 months

change from baseline, improvement

Secondary/protocol endpoint

Change in Triglycerides

Time frame:Baseline, 3 months, and 6 months

change from baseline, improvement

Secondary/protocol endpoint

Change in High-Density Lipoprotein Cholesterol (HDL-C)

Time frame:Baseline, 3 months, and 6 months

change from baseline, improvement

Secondary/protocol endpoint

Change in Total Cholesterol (TC)

Time frame:Baseline, 3 months, and 6 months

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateNovember 5, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the November 5, 2026 snapshot.